AxoGen, Inc. (AXGN) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Medical - Devices
EV/EBITDA
↑
6473.52
↑+187% vs avg
5yr avg: 2251.70
30Y Low0.1·High95.3
P/FCF
N/A
—
5yr avg: 66306.53
30Y Low1.1·High12.7
P/B Ratio
↑
15.54
↑+165% vs avg
5yr avg: 5.87
30Y Low1.3·High37.5
ROE
↑
-13.5%
↓+29% vs avg
5yr avg: -19.1%
30Y Low-315%·High265%
Debt/EBITDA
↑
55.94
↑+57% vs avg
5yr avg: 35.52
30Y Low0.0·High15.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AXGN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
AxoGen, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.2B | $1.5B | $729M | $293M | $420M | $386M | $715M | $702M | $759M | $943M | $276M |
| Enterprise Value | $2.2B | $1.5B | $771M | $331M | $472M | $421M | $721M | $671M | $734M | $931M | $271M |
| P/E Ratio → | -127.88 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 9.96 | 6.69 | 3.89 | 1.84 | 3.03 | 3.03 | 6.37 | 6.58 | 9.04 | 15.61 | 6.72 |
| P/B Ratio | 15.54 | 11.70 | 7.02 | 3.06 | 4.16 | 3.43 | 5.81 | 5.31 | 5.16 | 37.45 | 18.52 |
| P/FCF | — | — | 66306.53 | — | — | — | — | — | — | — | — |
| P/OCF | 2762.56 | 1856.19 | 160.83 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
AXGN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
AxoGen, Inc.'s enterprise value stands at 6473.5x EBITDA, 187% above its 5-year average of 2251.7x. The Healthcare sector median is 14.1x, placing the stock at a 45717% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.62 | 4.11 | 2.08 | 3.41 | 3.30 | 6.42 | 6.29 | 8.75 | 15.41 | 6.58 |
| EV / EBITDA | 6473.52 | 4334.07 | 169.34 | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | 70045.80 | — | — | — | — | — | — | — | — |
AXGN Profitability
Margins and return-on-capital ratios measuring operating efficiency
AxoGen, Inc. earns an operating margin of -3.5%. Operating margins have expanded from -13.5% to -3.5% over the past 3 years, signaling improving operational efficiency. A negative ROE of -13.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.3% | 74.3% | 75.8% | 76.6% | 78.5% | 82.0% | 80.8% | 83.7% | 84.6% | 84.6% | 84.3% |
| Operating Margin | -3.5% | -3.5% | -1.8% | -13.5% | -21.4% | -20.0% | -20.6% | -29.4% | -24.4% | -13.2% | -19.8% |
| Net Profit Margin | -7.0% | -7.0% | -5.3% | -13.7% | -20.9% | -21.2% | -21.2% | -27.3% | -26.7% | -17.3% | -35.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -13.5% | -13.5% | -10.0% | -22.1% | -27.1% | -22.9% | -18.6% | -20.9% | -26.0% | -52.1% | -124.7% |
| ROA | -7.4% | -7.4% | -5.0% | -11.1% | -14.4% | -13.2% | -13.4% | -18.5% | -20.4% | -19.9% | -34.4% |
| ROIC | -4.6% | -4.6% | -1.8% | -11.2% | -14.8% | -13.8% | -15.1% | -21.0% | -22.6% | -52.9% | -71.5% |
| ROCE | -4.2% | -4.2% | -1.9% | -12.7% | -16.7% | -14.0% | -14.8% | -22.4% | -21.3% | -19.8% | -23.5% |
AXGN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
AxoGen, Inc. carries a Debt/EBITDA ratio of 55.9x, which is highly leveraged (1620% above the sector average of 3.3x). The company holds a net cash position — cash of $36M exceeds total debt of $19M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.15 | 0.15 | 0.66 | 0.72 | 0.67 | 0.60 | 0.44 | 0.04 | 0.00 | 0.98 | 1.63 |
| Debt / EBITDA | 55.94 | 55.94 | 15.10 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.13 | 0.40 | 0.40 | 0.52 | 0.31 | 0.05 | -0.23 | -0.16 | -0.47 | -0.38 |
| Net Debt / EBITDA | -47.40 | -47.40 | 9.04 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | 3739.27 | — | — | — | — | — | — | — | — |
| Interest Coverage | -1.04 | -1.04 | -0.21 | -6.66 | -45.39 | -18.90 | -21.57 | -727.38 | -17.54 | -3.24 | -1.30 |
Net cash position: cash ($36M) exceeds total debt ($19M)
AXGN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
AxoGen, Inc.'s current ratio of 5.11x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.31x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 2.89x to 5.11x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.11 | 5.11 | 3.24 | 2.89 | 4.13 | 5.23 | 6.36 | 6.47 | 11.57 | 4.06 | 3.97 |
| Quick Ratio | 3.31 | 3.31 | 2.16 | 2.14 | 3.33 | 4.54 | 5.81 | 5.80 | 10.65 | 3.53 | 3.48 |
| Cash Ratio | 1.51 | 1.51 | 1.09 | 1.02 | 2.05 | 3.46 | 4.55 | 4.62 | 8.94 | 2.66 | 2.71 |
| Asset Turnover | — | 1.02 | 0.92 | 0.81 | 0.71 | 0.61 | 0.56 | 0.69 | 0.52 | 1.03 | 0.89 |
| Inventory Turnover | 1.37 | 1.37 | 1.37 | 1.61 | 1.57 | 1.37 | 1.72 | 1.25 | 1.08 | 1.27 | 1.18 |
| Days Sales Outstanding | — | 42.41 | 46.97 | 57.72 | 58.43 | 52.04 | 57.26 | 57.96 | 66.62 | 66.84 | 71.50 |
AXGN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
AxoGen, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | 0.0% | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $46M | $44M | $43M | $42M | $41M | $40M | $39M | $37M | $33M | $31M |
Peer Comparison
Compare AXGN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AXGNYou | $2B | -127.9 | 6473.5 | — | 74.3% | -3.5% | -13.5% | -4.6% | 55.9 |
 TELA | $40M | -0.7 | — | — | 67.1% | -49.2% | -159.9% | -151.6% | — |
 NVCR | $2B | -13.5 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 XTNT | $81M | -4.8 | — | — | 58.2% | -10.3% | -34.9% | -12.8% | — |
 MDXG | $544M | 11.4 | 5.1 | 7.5 | 82.6% | 15.3% | 21.6% | 42.3% | 0.3 |
 ANIK | $203M | -19.9 | — | 46.5 | 56.6% | -9.8% | -7.3% | -7.1% | — |
 RGEN | $7B | 146.2 | 52.2 | 75.5 | 47.1% | 8.1% | 2.4% | 2.2% | 5.0 |
 ISRG | $160B | 57.4 | 43.4 | 64.4 | 66.0% | 29.3% | 16.6% | 15.0% | 0.1 |
 SYK | $112B | 34.8 | 20.2 | 26.1 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
 ZBH | $16B | 23.3 | 9.4 | 11.0 | 61.6% | 16.5% | 5.6% | 5.4% | 3.1 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See AXGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AXGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AXGN vs TELA
Side-by-side business, growth, and profitability comparison vs TELA Bio, Inc..
Start ComparisonAXGN — Frequently Asked Questions
Quick answers to the most common questions about buying AXGN stock.
What is AxoGen, Inc.'s P/E ratio?
AxoGen, Inc.'s current P/E ratio is -127.9x. The historical average is 3.5x.
What is AxoGen, Inc.'s EV/EBITDA?
AxoGen, Inc.'s current EV/EBITDA is 6473.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 38.9x.
What is AxoGen, Inc.'s ROE?
AxoGen, Inc.'s return on equity (ROE) is -13.5%. The historical average is -35.1%.
Is AXGN stock overvalued?
Based on historical data, AxoGen, Inc. is trading at a P/E of -127.9x. Compare with industry peers and growth rates for a complete picture.
What are AxoGen, Inc.'s profit margins?
AxoGen, Inc. has 74.3% gross margin and -3.5% operating margin.
How much debt does AxoGen, Inc. have?
AxoGen, Inc.'s Debt/EBITDA ratio is 55.9x, indicating high leverage. A ratio above 4x may signal elevated financial risk.